Spatial Biomarkers and Immunotherapy Response
Multiplex imaging of the tumor microenvironment could reveal new insights
Cliff Hoyt | | Opinion
Delivering on the promise of precision medicine in oncology depends on the predictive performance of biomarker tests. Immuno-oncology treatments can be lifesaving – but only for a fraction of patients. Put simply, the predictive biomarkers available today don’t always accurately identify the patients who will respond, leading to higher incidences of adverse events and treatment resistance. Conventional immunohistochemistry (IHC) techniques assessing PD-L1 expression and, to a lesser degree, microsatellite instability status are currently the only clinically validated predictive biomarkers for checkpoint inhibitors. However, most experts agree that neither assay is sufficient; some lead to false positives or false negatives, whereas others address only a small fraction of the patient population. There is much room for improvement.
Read the full article now
Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Pathologist magazine